What is LYRA's dilution risk score?

LYRA has a latest available DilutionScore record of 69/100, categorized as high dilution risk by the DilutionWatch scoring model. DilutionWatch displays SEC filing and dilution indicators for LYRA, including shelf registrations, ATM offerings, warrant exercises, PIPE deals, and reverse split signals when detected in source data.

What SEC filings does DilutionWatch track for LYRA?

DilutionWatch tracks 25 SEC filing types for LYRA including S-3 shelf registrations, 424B prospectuses (ATM offerings), S-1 registration statements, 8-K material events, warrant exercise notices, convertible note agreements, and Form 4 insider transactions. Alerts are delivered via email within minutes of a filing appearing on EDGAR.

How does stock dilution affect LYRA shareholders?

Stock dilution occurs when a company issues new shares, reducing the ownership percentage of existing shareholders. For LYRA, common dilution events include at-the-market (ATM) stock offerings, shelf registration drawdowns, warrant exercises, and convertible note conversions. Each event increases the share count and can pressure the stock price lower.

Is DilutionWatch free for LYRA tracking?

DilutionWatch provides a free tier that shows DilutionScores and basic filing history for LYRA. Premium plans ($19.95/month Basic, $39.95/month Premium) unlock real-time email alerts, the full Pulse™ feed, advanced dilution forecasts, and access to all 10,000+ tracked tickers.

LYRA Dilution Risk Score: 69/100 (HIGH)

Score Breakdown

📋 Offering Ability

46

💰 Cash Runway

85

📊 Float Risk

77

⚠️ Warrant Exposure

40

🔄 Convertible Debt

40

Dilution Forecast

⛈️

Warning

High probability of dilution event

model est. 47%

🔄 Reverse Split model est. 70%

• 50-day avg $0.66 below $1 exchange minimum

• Only 3 months cash — financial pressure

💰 Capital Raise model 35%

• Low cash runway: 3 months remaining

📉 Score Deterioration model 10%

• Score in HIGH risk zone (69/100)

🔔 Track LYRA — Get forecast alerts →

Market Data

Market Cap$1.31M

Shares Outstanding1.77M

Float336.1K

Cash$15.89M

Debt$30.26M

Short InterestN/A

Institutional Holdings

QoQ: ↓ 56.5% shares (2026Q1 vs prior)

2 institutional holders · 105.7K shares

#1 SABBY MANAGEMENT, LLC 104.1K shares

#2 MORGAN STANLEY 1.6K shares

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest5.0K

Days to Cover1.7

% of Float1.5%

FINRA data as of Jul 31, 2026

Insider Buy/Sell Ratio

Recent SEC Activity

xbrl XBRL WARRANT 2024-09-30

xbrl XBRL CONVERTIBLE 2020-12-31

Full SEC filing analysis available with free account →

Recent News

No recent news

Factual LYRA Dilution Snapshot

Lyra Therapeutics, Inc. (LYRA) has a DilutionScore of 69/100, rated High dilution risk. Score date: August 28, 2026.

Recent SEC activity tracked for LYRA: xbrl on 2024-09-30; xbrl on 2020-12-31.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.